SEC Form 4 · accession 0001437749-15-005312
HYPERION THERAPEUTICS INC · HPTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine A Nash
Officer — SVP & Chief Commercial Officer
Period of report
Mar 17, 2015
Accepted (ET)
Mar 17, 2015 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 17, 2015 | M | 10,000 | $4.08 | A | 29,003 | D | |
| Common Stock | Mar 17, 2015 | S | 10,000 | $37.56 | D | 19,003 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $4.08 | Mar 17, 2015 | M | 10,000 | D | — | Apr 14, 2021 | Common Stock | 32,709 | 12,709 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014.
- F2The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions ranging in price from $37.50-37.65. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.
- F3The shares acquired upon exercise of portion of option exercised were fully vested and exercisable. The option began vesting on April 15, 2011, at a rate of 1/48th per month.